A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
BIOLOGICAL: C-CAR011
Safety: Vital signs, physical examination, clinical laboratory tests, incidence of adverse events (AEs) and serious adverse events (SAEs), Vital signs, physical examination, clinical laboratory tests, incidence of adverse events (AEs) and serious adverse events (SAEs), 12 weeks|Overall response rate (ORR), 12 weeks
Overall response rate (ORR), 6 months|Overall response rate (ORR), 12 months|Duration of remission (DOR), 12 months|Progression free survival (PFS), 12 months|Overall survival (OS), 12 months
The study will include the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), Treatment and Follow-up.